摘要:
The present invention relates to a crystalline form of gatifloxacin obtainable by a process that comprises recrystallisation of the crude gatifloxacin in methanol and which is stable with a water content ranging between 2.5 and 4.5% by weight, to a process for preparing it and to the use thereof as an active substance in the preparation of pharmaceutical formulations.
摘要:
Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10% aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a solvent or mixture of solvents; b) adding citric acid; and c) isolating the product obtained by crystallisation. The addition salts of azithromycin and citric acid are stable and soluble in aqueous medium, being useful antibacterial and antiprotozoan agents.
摘要:
The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia. Additionally, processes for preparing such derivatives and pharmaceutical compositions comprising them are provided.
摘要:
The present invention relates to a process of enantioselective enzymatic acylation for the preparation of (R)-2-halo-N-[2-(4-methoxyphenyl)-1-methyl-ethyl] acetamide compounds, of formula III, in which X═Cl, Br, I. These compounds (III) are useful as intermediates in the synthesis of tamsulosin hydrochloride.
摘要:
The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia. Additionally, processes for preparing such derivatives5 and pharmaceutical compositions comprising them are provided.
摘要:
This invention relates to a process for obtaining levofloxacin free from salts. In this process the starting product used is the compound (V), alkaline hydrolysis of which within a water-(C1-C4)alcohol mixture, and subsequent neutralisation and separation of the salts, leads to levofloxacin free from salts, without need to carry out any final step of extraction and without using halogenated solvents.One characteristic of the process described is that no extractions are necessary in the final step of the process.
摘要:
A new procedure is described for the selective preparation of crystalline polymorphs A and B of fosinopril, especially polymorph A. The procedure described allows to avoid the use of significant quantities of water, thus resulting in a lower risk of hydrolytic degradations of the active ingredient.